miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
复制标题
血浆小ev中的miR-18a和miR-106a特征是早期检测胰腺导管腺癌的有希望的生物标志物。
DOI：
10.3390/ijms24087215
复制
发表时间：
2023-04-13
影响因子：
5.6
通讯作者：
Ding, Wei-Qun
中科院分区：
文献类型：
--
作者：
Xu, Xiaohui;Bhandari, Kritisha;Xu, Chao;Morris, Katherine;Ding, Wei-Qun
胰腺癌是美国癌症相关死亡的第三大原因。胰腺导管腺癌（PDAC）是胰腺癌的主要形式，预后最差。早期发现是提高PDAC患者总生存率的关键。最近的研究表明，血浆小细胞外囊泡（EV）中的microRNA（miRNA）签名是早期检测PDAC的潜在生物标志物。然而，由于血浆小EV的异质性和用于小EV分离的方法，已发表的结果不一致。我们最近改进了使用双重过滤和超离心分离血浆小EV的过程。在本研究中，我们应用该方案，并通过小RNA测序和定量RT-PCR在试点队列中分析了血浆小EV miRNA特征，该队列由早期PDAC患者和年龄和性别匹配的健康受试者组成（n = 20）。我们通过小RNA测序发现，PDAC患者的血浆小EV中富集了几种miRNA，并且通过定量RT-PCR证实，与年龄和性别匹配的健康受试者相比，早期PDAC患者中miR-18 a和miR-106 a的水平显著升高。此外，使用基于免疫亲和性的血浆小EV分离方法，我们证实了PDAC患者血浆小EV中miR-18 a和miR-106 a的水平显著高于健康受试者。因此，我们得出结论，血浆小EV中miR-18 a和miR-106 a的水平是用于早期检测PDAC的有希望的生物标志物。
Pancreatic cancer is the third leading cause of cancer-related death in the United States. Pancreatic ductal adenocarcinoma (PDAC) is the major form of pancreatic cancer with the worst outcomes. Early detection is key to improving the overall survival rate of PDAC patients. Recent studies have demonstrated that microRNA (miRNA) signatures in plasma small extracellular vesicles (EVs) are potential biomarkers for the early detection of PDAC. However, published results are inconsistent due to the heterogeneity of plasma small EVs and the methods used for small EV isolation. We have recently refined the process of plasma small EV isolation using double filtration and ultracentrifugation. In the present study, we applied this protocol and analyzed plasma small EV miRNA signatures by small RNA sequencing and quantitative RT-PCR in a pilot cohort, consisting of patients with early-stage PDAC, and age- and gender-matched healthy subjects (n = 20). We found, via small RNA sequencing, that there are several miRNAs enriched in plasma small EVs of PDAC patients, and the levels of miR-18a and miR-106a were confirmed by quantitative RT-PCR to be significantly elevated in patients with early-stage PDAC compared with age- and gender-matched healthy subjects. Furthermore, using an immunoaffinity-based plasma small EV isolation approach, we confirmed that the levels of miR-18a and miR-106a in plasma small EVs were significantly higher in PDAC patients versus the healthy subjects. We thus conclude that the levels of miR-18a and miR-106a in plasma small EVs are promising biomarkers for the early detection of PDAC.
登录
查看更多内容
影响因子：
9.7
作者：
Lai X;Wang M;McElyea SD;Sherman S;House M;Korc M
通讯作者：
Korc M
影响因子：
--
作者：
Xu YF;Hannafon BN;Zhao YD;Postier RG;Ding WQ
通讯作者：
Ding WQ
影响因子：
3.7
作者：
Xu YF;Xu X;Bhandari K;Gin A;Rao CV;Morris KT;Hannafon BN;Ding WQ
通讯作者：
Ding WQ
影响因子：
6.8
作者：
Kofanova, Olga;Henry, Estelle;Betsou, Fay
通讯作者：
Betsou, Fay
影响因子：
4.1
作者：
Xu, Yi-Fan;Hannafon, Bethany N.;Ding, Wei-Qun
通讯作者：
Ding, Wei-Qun